... oxadiazoles MeSH D03.383.129.462.580.200 --- 5-amino-3-((5-nitro-2-furyl)vinyl)-1,2,4-oxadiazole MeSH D03.383.129.462.580.400 ... vinyl)-1,2,4-oxadiazole MeSH D03.383.312.649.290 --- fanft MeSH D03.383.312.649.308 --- furagin MeSH D03.383.312.649.313 --- ... alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid MeSH D03.383.129.385.162 --- cycloserine MeSH D03.383.129.385.231 --- ... 2,3,4,5-tetrahydro-8-chloro-3-methyl-5-phenyl-1h-3-benzazepin-7-ol MeSH D03.438.079.800 --- 2,3,4,5-tetrahydro-7,8-dihydroxy-1- ...

... vinyl)-1,2,4-oxadiazole MeSH D02.640.600.290 --- fanft MeSH D02.640.600.308 --- furagin MeSH D02.640.600.313 --- furazolidone ... vinyl compounds MeSH D02.455.326.271.884.533 --- polyvinyls MeSH D02.455.326.271.884.533.532 --- polyvinyl alcohol MeSH D02.455 ... vinyl chloride MeSH D02.455.326.397 --- alkynes MeSH D02.455.326.397.259 --- acetylene MeSH D02.455.326.397.300 --- ... vinyl chloride MeSH D02.455.526.510 --- hydrocarbons, fluorinated MeSH D02.455.526.510.140 --- chlorofluorocarbons MeSH D02.455 ...

... (Picovir) is an antiviral drug that was being developed by Schering-Plough for prevention of asthma exacerbations and common cold symptoms in patients exposed to picornavirus respiratory infections. Pleconaril, administered either orally or intranasally, is active against viruses in the Picornaviridae family, including Enterovirus and Rhinovirus. It has shown useful activity against the dangerous strain enterovirus D68. Pleconaril was originally developed by Sanofi-Aventis, and licensed to ViroPharma in 1997. ViroPharma developed it further, and submitted a New Drug Application to the United States Food and Drug Administration (FDA) in 2001. The application was rejected, citing safety concerns; and ViroPharma re-licensed it to Schering-Plough in 2003. The Phase II clinical trial was completed in 2007. A pleconaril intranasal spray had reached phase II clinical trial for the treatment of the common cold symptoms and asthma complications. However, the results have yet to be reported. In ...

Most NONOates are stable in alkaline solution above pH 8.0 (e. g. 10 mM NaOH) and can be stored at −20 °C in this way for the short term. To generate NO from NONOates, the pH is lowered accordingly. Typically, a dilution of the stock NONOate solution is made in a phosphate buffer (pH 7.4; tris buffers can also be used) and incubated at room temperature for the desired time to allow NO to accumulate in solution. This is often visible as bubbles at high NONOate concentrations. Incubation time is important, since the different NONOates have different half-lives (t½) in phosphate buffer at pH 7.4. For example, the half-life of MAHMA NONOate under these conditions is ~3.5 minutes, whilst the t½ of DPTA NONOate is 300 minutes. This is often useful in biological systems, where a combination of different NONOates can be used to give a sustained release of nitric oxide. At pH 5.0, most NONOates are considered to decompose almost instantaneously. ...

... (DVB) consists of a benzene ring bonded to two vinyl groups. It is related to styrene (vinylbenzene) by the addition of a second vinyl group.[2] It is a colorless liquid manufactured by the thermal dehydrogenation of isomeric diethylbenzenes. Under synthesis conditions, o-divinylbenzene converts to naphthalene and thus is not a component of the usual mixtures of DVB.[3] ...

An additional stabilizing factor in this enzyme-substrate complex is hydrogen bonding between the lone pair of the oxygen in the vinyl ether system and hydrogen bond donor residues. Not only does this stabilize the complex, but disruption of resonance within the vinyl ether destabilizes the ground state and reduces the energy barrier for this transformation. An alternative view is that electrostatic stabilization of the polarized transition state is of great importance in this reaction. In the chorismate mutase active site, the transition-state analog is stabilized by 12 electrostatic and hydrogen-bonding interactions.[8] This is shown in mutants of the native enzyme in which Arg90 is replaced with citrulline to demonstrate the importance of hydrogen bonding to stabilize the transition state.[9] Other work using chorismate mutase from Bacillus subtilis showed evidence that when a cation was aptly placed in the active site, the electrostatic interactions between it and the ...

... is the property of being toxic to the ear (oto-), specifically the cochlea or auditory nerve and sometimes the vestibular system, for example, as a side effect of a drug. The effects of ototoxicity can be reversible and temporary, or irreversible and permanent. It has been recognized since the 19th century. There are many well-known ototoxic drugs used in clinical situations, and they are prescribed, despite the risk of hearing disorders, to very serious health conditions. Ototoxic drugs include antibiotics such as gentamicin, loop diuretics such as furosemide and platinum-based chemotherapy agents such as cisplatin. A number of nonsteroidal anti-inflammatory drugs (NSAIDS) have also been shown to be ototoxic.[citation needed] This can result in sensorineural hearing loss, dysequilibrium, or both. Some environmental and occupational chemicals have also been shown to affect the auditory system and interact with noise. Symptoms of ototoxicity include partial or profound hearing loss, ...

The Petasis reaction (alternatively called the Petasis borono-Mannich (PBM) reaction) is the chemical reaction of an amine, aldehyde, and vinyl- or aryl-boronic acid to form substituted amines. Reported in 1993 by Nicos Petasis as a practical method towards the synthesis of a geometrically pure antifungal agent, naftifine, the Petasis reaction can be described as a variation of the Mannich reaction. Rather than generating an enolate to form the substituted amine product, in the Petasis reaction, the vinyl group of the organoboronic acid serves as the nucleophile. In comparison to other methods of generating allyl amines, the Petasis reaction tolerates a multifunctional scaffold, with a variety of amines and organoboronic acids as potential starting materials. Additionally, the reaction does not require anhydrous or inert conditions. As a mild, selective synthesis, the Petasis reaction is useful in generating α-amino acids, and is utilized in combinatorial ...

Allylstannanes are relatively stable reagents in the allylmetal family, and have been employed in a variety of complex organic syntheses. In fact, allylstannane addition is one of the most common methods for producing polypropionates, polyacetates, and other oxygenated molecules with a contiguous arrays of stereocenters.[10] Ley and coworkers[11] used an allylstannane to allylate a threose-derived aldehyde (see figure) en route to the macrolide antascomicin B, which structurally resembles FK506 and rapamycin, and is a potent binder of FKBP12. Allylboration is also often used to add allyl groups in a 1,2 fashion to aldehydes and ketones. Thanks to decades of research, there is now a wide variety of organoboron reagents available to the synthetic chemist, including organoboranes that predictably yield products in high diastereo- and enantioselectivity.[12] If a one-pot metal insertion and allylation procedure is required, indium- mediated allylation is an attractive option for generating ...

Nurse is the first major label album released by the band Therapy?.[3] It was released on 2 November 1992 on A&M Records. The album was mainly recorded at Loco Studio in Caerleon, Wales, apart from "Gone" which was recorded in Annamoe, Ireland.[4] It marked a departure from the noise punk style of the two mini-albums, being a more industrial-sounding record. The album was rated favourably by critics and reached number 38 in the UK Albums Chart.[5]. The album was released on 12" vinyl, CD and cassette. In the US, the album was released on limited edition red 12" vinyl, CD and cassette.. A remastered CD version of the album by the original producer, Harvey Birrell, was included in The Gemil Box, released on 18 November 2013.. The original master of the album was used for a 'Music on Vinyl' audiophile re-issue, released on mixed red and gold 180g vinyl on 22 February 2016, limited to 1000 copies[6]. The album can be seen in the background of a ...

Edison Laser Player (ELP) Japan is a Japanese audio equipment company started by Sanju Chiba, who manufacture laser turntables. The origin of ELP's turntable came from an American company named Finial Technologies, led by Michael Stoddard, who designed a prototype unit for playing vinyl using laser technology in the mid-1980s. Unfortunately, this coincided with the commercial rise of the CD, so Finial went into receivership and sold the rights to ELP in 1989. The units are custom built to order - a typical price in the mid-2000s was about $11,000 to $15,000. The turntable uses a combination of five lasers, which point in different directions of the groove in a vinyl record to ensure a steady signal is picked up. Because of laser technology, loading and unloading a vinyl record is similar to the process used in most high end CD players. The lack of mechanical components means it is far more capable of playing records, even those with scratches and warps, and ...

To avoid over-hyping the album, DGC Records took a low-key approach to promoting In Utero; the company's head of marketing told Billboard before the album's release that the label was taking a promotional strategy similar to that of Nevermind, and explained that the label would "set things up, duck, and get out of the way". The label aimed its promotion at alternative markets and press, and released the album on vinyl record as part of this strategy.[74] In contrast to the previous album, the label did not release any of In Utero's singles commercially in the United States.[8] DGC sent promo copies of the album's first single, "Heart-Shaped Box", to American college, modern rock, and album-oriented rock radio stations in early September, but the label did not target Top 40 radio.[74] Despite the label's promotion, the band was convinced that In Utero would not be as successful as Nevermind. Cobain told Jim DeRogatis, "We're certain that we won't sell a quarter as much, and we're totally ...

... are a post-rock band based in the English cities of Leicester and Leeds. After playing live throughout the United Kingdom to much critical acclaim, with the likes of iLiKETRAiNS and The Twilight Sad, they released their debut album, The Heritage, in 2008, which was also positively acclaimed, and was followed by a well-received headlining tour. The album lasts over 50 minutes, despite only containing six tracks. In February 2009, they announced their arrival on the German label, Denovali Records. Denovali re-released The Heritage on vinyl in late 2009. The band released The Quiet Lamb, containing 12 tracks and lasting over 75 minutes, on 8 November 2010. NME gave it a score of 8/10, describing it as "massive, pastorally apocalyptic music". The Sun called it a "ten-track jewel of a record" that engages the listener "in a rare and beautiful way". The Quiet Lamb is ranked the 12th best Post Rock album of all time in a poll of fans and reviewers with a critic's score of 83. In 2014 ...

Irregular bleeding and spotting: Many women will experience some type of irregular, unpredictable, prolonged, frequent, or infrequent bleeding when using Nexplanon or Implanon.[18] Some women also experience amenorrhea. For some women, prolonged bleeding will decline after the first three months of use. However, other women may experience this bleeding pattern through all three years of use. While these patterns are not dangerous, they are the most common reason that women give for discontinuing the use of the implant. After removal, bleeding patterns return to previous patterns in most women.[13][14][15][16]. Insertion complications: Some minor side effects such as bruising, skin irritation, or pain around the insertion site are common.[13] However, there are some rare complications that can occur, such as infection or expulsion.[13][19] In some cases, a serious complication occurs when the provider fails to insert, and the rod is left in the inserter. An Australian study reported 84 ...

Born in Aachen in 1810, he moved to Paris at the age of eight, following the death of his parents. There, he worked for an upholstery firm until he was eighteen. In 1830, he was admitted to the École Polytechnique, and in 1832 he graduated from the École des mines. Working under Justus von Liebig at Gießen, Regnault distinguished himself in the nascent field of organic chemistry by synthesizing several chlorinated hydrocarbons (e.g. vinyl chloride[1], polyvinylidene chloride, dichloromethane), and he was appointed professor of chemistry at the University of Lyon. In 1840, he was appointed the chair of chemistry of the École Polytechnique, and in 1841, he became a professor of Physics in the Collège de France. Beginning in 1843, he began compiling extensive numerical tables on the properties of steam. These were published in 1847, and led to his receiving the Rumford Medal of the Royal Society of London and appointment as Chief Engineer of Mines. In 1851 he was elected a ...